Market Snapshot
  • U.S.
  • Europe
  • Asia
Ticker Volume Price Price Delta
DJIA 16,408.54 -16.31 -0.10%
S&P 500 1,864.85 2.54 0.14%
NASDAQ 4,095.52 9.29 0.23%
Ticker Volume Price Price Delta
STOXX 50 3,155.81 16.55 0.53%
FTSE 100 6,625.25 41.08 0.62%
DAX 9,409.71 91.89 0.99%
Ticker Volume Price Price Delta
NIKKEI 14,516.27 98.74 0.68%
TOPIX 1,173.37 6.78 0.58%
HANG SENG 22,760.24 64.23 0.28%

Lightlake Therapeutics Appoints Board Member as New Chief Financial Officer



 Lightlake Therapeutics Appoints Board Member as New Chief Financial Officer

PR Newswire

LONDON, Nov. 29, 2012

LONDON, Nov. 29, 2012 /PRNewswire/ -- Lightlake Therapeutics Inc. (LLTP) (the
"Company" or "Lightlake"), an early stage biopharmaceutical company developing
modern addiction treatments based on its expertise using opioid antagonists,
announced today that it has appointed Mr. Kevin Pollack, who has been a member
of Lightlake's Board of Directors since April 2012, as the Company's new Chief
Financial Officer.

"It has been a privilege to work with Kevin since he joined our Board and when
we look to our future as a company, we believe now is the appropriate time to
appoint him as our CFO," said Dr. Roger Crystal, Chief Executive of Lightlake.
"Kevin has demonstrated to us his expertise in both finance and strategy while
serving on our Board, and by appointing him as our CFO we believe he will be
in a better position to utilize his talents as we strive to build a platform
of biopharmaceutical solutions to common addictions and related disorders."

In addition to his duties at Lightlake, Mr. Pollack is also a Managing
Director at Paragon Capital, a private investment firm focused primarily on
investing in U.S.-listed companies. He also serves as President of Short Hills
Capital LLC, where he provides a range of advisory services to investors,
asset management firms, institutions, and companies. Mr. Pollack currently
sits on the Board of Directors of MagneGas Corporation, the developer of a
technology that converts liquid waste into a hydrogen-based metal working fuel
and natural gas alternative, as well as Pressure BioSciences, Inc., which
develops, markets and sells proprietary laboratory instrumentation and
associated consumables based on Pressure Cycling Technology.

Mr. Pollack's past experiences include working as an investment banker at Banc
of America Securities LLC, focusing on corporate finance and on mergers and
acquisitions. He started his career at Sidley Austin LLP (formerly Brown &
Wood LLP) as a securities attorney focusing on corporate finance and on
mergers and acquisitions. He graduated magna cum laude from The Wharton School
of the University of Pennsylvania and received a dual J.D./M.B.A. from
Vanderbilt University, where he graduated with Beta Gamma Sigma honors.

About Lightlake Therapeutics Inc.

Lightlake Therapeutics Inc. is a developing biopharmaceutical company aiming
to build a platform of biopharmaceutical solutions to common addictions and
related disorders. Currently, the Company is focused on providing a safe,
effective and simple treatment for patients who are obese or overweight as a
result of Binge Eating Disorder in addition to those patients suffering from
Bulimia Nervosa. Lightlake recently acquired patents that will allow it to
widen its product pipeline to address patients with addictions to opioid
painkillers, methadone, cocaine and amphetamine. The Company anticipates
launching a development program for each of these purposes in the future.

Safe Harbor

This press release contains forward-looking statements. These statements
relate to future events or our future financial performance and involve known
and unknown risks, uncertainties and other factors that may cause our or our
industry's actual results, levels of activity, performance or achievements to
be materially different from any future results, levels of activity,
performance or achievements expressed, implied or inferred by these
forward-looking statements. In some cases, you can identify forward-looking
statements by terminology such as "may," "will," "should," "could," "would,"
"expects," "plans," "intends," "anticipates," "believes," estimates,"
"predicts," "projects," "potential" or "continue" or the negative of such
terms and other comparable terminology. These statements are only predictions
based on our current expectations and projections about future events. You
should not place undue reliance on these statements. Actual events or results
may differ materially. In evaluating these statements, you should specifically
consider various factors. These and other factors may cause our actual results
to differ materially from any forward- looking statement. We undertake no
obligation to update any of the forward-looking statements after the date of
this presentation to conform those statements to reflect the occurrence of
unanticipated events, except as required by applicable law.

Contact:

Investor  
Mr. Kevin Fickle 
President 
NUWA Group LLC 
Tel: +1-925-330-8315 
Email: kevin@nuwagroup.com

Company  
Dr. Roger Crystal 
Lightlake Therapeutics Inc.  
Tel: +44(0)-203-617-8739 
Email: roger.crystal@lightlaketherapeutics.com

SOURCE Lightlake Therapeutics Inc.
Sponsored Links
Advertisement
Advertisements
Sponsored Links
Advertisement